Kura Oncology Inc (KURA): Next-Year EPS Estimate 25.36%
As of 2026-10-10, Kura Oncology Inc (KURA) has a next-year EPS growth estimate of 25.36%. Featured in 2 EPS revision reports, most recently on 2026-08-19.
On 2026-10-01, analyst consensus for KURA's next-year EPS growth shifted from 26.31% to 25.36% — a negative change of 0.95 percentage points. The revised estimate has been sustained across 10 subsequent trading sessions. Current-year growth is projected at -1.34%.
What's Driving This
The stock’s rise is primarily tied to an upward revision in next-year EPS growth estimates, from 25.78% to 26.30% on August 24. That revision likely followed the Q2 2026 earnings report, whose financial results may have exceeded expectations. Positive clinical updates for ziftomenib and darlifarnib also supported sentiment, helping sustain momentum beyond the initial upgrade.
Generated 2026-08-31 from news as of 2026-08-31
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 25.36%
- EPS growth this year
- -1.34%
- EPS next quarter (est)
- -$0.81
- Last price
- $10.60
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-10 | 25.36% | -1.34% | -$0.81 | $10.60 |
| 2026-10-09 | 25.36% | -1.34% | -$0.81 | $10.60 |
| 2026-10-08 | 25.36% | -1.34% | -$0.81 | $10.52 |
| 2026-10-07 | 25.36% | -1.34% | -$0.81 | $10.67 |
| 2026-10-06 | 25.36% | -1.34% | -$0.81 | $10.53 |
| 2026-10-05 | 25.36% | -1.34% | -$0.81 | $10.62 |
| 2026-10-04 | 25.36% | -1.34% | -$0.81 | $10.65 |
| 2026-10-03 | 25.36% | -1.34% | -$0.81 | $10.65 |
| 2026-10-02 | 25.36% | -1.34% | -$0.81 | $10.65 |
| 2026-10-01 | 25.36% | -1.34% | -$0.81 | $10.65 |
| 2026-09-30 | 26.31% | -1.27% | -$0.82 | $10.71 |
| 2026-09-29 | 26.31% | -1.27% | -$0.82 | $10.81 |
| 2026-09-28 | 26.31% | -1.27% | -$0.82 | $10.61 |
| 2026-09-27 | 26.31% | -1.27% | -$0.82 | $10.76 |
| 2026-09-25 | 26.31% | -1.27% | -$0.82 | $10.76 |
| 2026-09-24 | 26.31% | -1.27% | -$0.82 | $10.86 |
| 2026-09-23 | 26.31% | -1.27% | -$0.82 | $11.04 |
| 2026-09-22 | 26.31% | -1.27% | -$0.82 | $11.73 |
| 2026-09-21 | 26.31% | -1.27% | -$0.82 | $11.60 |
| 2026-09-20 | 26.31% | -1.27% | -$0.82 | $11.73 |
| 2026-09-18 | 26.31% | -1.27% | -$0.82 | $11.73 |
| 2026-09-17 | 26.31% | -1.27% | -$0.82 | $11.72 |
| 2026-09-16 | 26.31% | -1.27% | -$0.82 | $11.20 |
| 2026-09-15 | 26.31% | -1.27% | -$0.82 | $11.30 |
| 2026-09-14 | 26.31% | -1.27% | -$0.82 | $11.56 |
| 2026-09-13 | 26.31% | -1.27% | -$0.82 | $11.39 |
| 2026-09-11 | 26.31% | -1.27% | -$0.82 | $11.39 |
| 2026-09-10 | 26.31% | -1.27% | -$0.82 | $11.57 |
| 2026-09-09 | 26.31% | -1.27% | -$0.82 | $12.09 |
| 2026-09-08 | 26.30% | -1.28% | -$0.82 | $12.52 |
Reports Featuring KURA
Recent News
- Kura spins diabetes work into a Lilly-backed biotech startupBioPharma Dive
- Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for DiabetesGlobeNewswire
- Kura Oncology Appoints Jennifer Fulk as Chief Financial OfficerGlobeNewswire
- Kura Oncology, Inc. Q2 2026 Earnings Call SummaryMoby
- Kura Oncology: Q2 Earnings SnapshotAssociated Press
- Kura Oncology Reports Second Quarter 2026 Financial ResultsGlobeNewswire
- Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026GlobeNewswire
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AMLGlobeNewswire
- Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development StrategyGlobeNewswire
Screen Performance
Aggregate stats across all 2077 tickers our top-EPS-revision screen has flagged over the past 192 days.
- Median return since detection
- -0.9%
- % of tickers in the green
- 47%
- Median return on winners
- +23.2%
- Large revisions captured
- 1848
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Kura Oncology Inc's next-year EPS growth estimate?▾
As of 2026-10-10, Kura Oncology Inc (KURA) has a next-year EPS growth estimate of 25.36%, based on analyst consensus.
When was the latest EPS estimate revision for KURA?▾
The most recent revision occurred on 2026-10-01, when analysts adjusted the next-year EPS growth estimate from 26.31% to 25.36%.
What sector and industry does Kura Oncology Inc belong to?▾
Kura Oncology Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. KURA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Kura Oncology Inc (KURA) appears here because it was detected by our daily top-EPS-revision-performer screen.